Table 5.
Association of autoantibodies having a prevalence >10% with Mayo risk score, AMA results, associated autoimmune conditions, hepatic decompensation and response of treatment with UDCA in 109 PBC patients.
| Autoantibody (frequency) | Positive (+) | Negative (−) | P-value | |
|---|---|---|---|---|
| M2 (82%) | Mayo risk score, median (IQR) | 4·0 (3·6–4·6) | 4·2 (3·7–4·5) | 0·95 |
| AMA-positive, n (%) | 88 (99) | 15 (75) | 0·001 | |
| Associated autoimmune conditions, n (%) | 18 (20) | 3 (15) | 0·76 | |
| Hepatic decompensation, n (%) | 6 (7) | 1 (5) | 1 | |
| Response to UDCA, n (%) | 41 (55) | 10 (63) | 0·78 | |
| 3E-BPO (73%) | Mayo risk score, median (IQR) | 4·0 (3·6–4·7) | 4·1 (3·7–4·5) | 0·6 |
| AMA-positive, n (%) | 79 (99) | 24 (83) | 0·005 | |
| Associated autoimmune conditions, n (%) | 16 (20) | 5 (17) | 1 | |
| Hepatic decompensation, n (%) | 6 (8) | 1 (3) | 0·67 | |
| Response to UDCA, n (%) | 33 (49) | 18 (82) | 0·007 | |
| Ro52 (32%) | Mayo risk score, median (IQR) | 4·0 (3·7–4·6) | 4·1 (3·6–4·6) | 0·79 |
| AMA-positive, n (%) | 31 (89) | 72 (97) | 0·08 | |
| Associated autoimmune conditions, n (%) | 10 (29) | 11 (15) | 0·12 | |
| Hepatic decompensation, n (%) | 2 (6) | 5 (7) | 1 | |
| Response to UDCA, n (%) | 11 (52) | 40 (58) | 0·8 | |
| RAP55 (28%) | Mayo risk score, median (IQR) | 3·9 (3·3–4·4) | 4·1 (3·7–4·8) | 0·13 |
| AMA-positive, n (%) | 30 (97) | 73 (94) | 0·67 | |
| Associated autoimmune conditions, n (%) | 6 (19) | 15 (19) | 1 | |
| Hepatic decompensation, n (%) | 2 (6) | 5 (6) | 1 | |
| Response to UDCA, n (%) | 17 (59) | 34 (56) | 0·82 | |
| gp210 (27%) | Mayo risk score, median (IQR) | 4·4 (3·8–4·6) | 4·0 (3·6–4·6) | 0·07 |
| AMA-positive, n (%) | 29 (97) | 74 (94) | 1 | |
| Associated autoimmune conditions, n (%) | 4 (13) | 17 (22) | 0·42 | |
| Hepatic decompensation, n (%) | 2 (7) | 5 (6) | 1 | |
| Response to UDCA, n (%) | 12 (52) | 39 (58) | 0·63 | |
| Sp100 (27%) | Mayo risk score, median (IQR) | 4·0 (3·7–4·5) | 4·1 (3·6–4·6) | 0·65 |
| AMA-positive, n (%) | 28 (97) | 75 (94) | 1 | |
| Associated autoimmune conditions, n (%) | 3 (10) | 18 (23) | 0·18 | |
| Hepatic decompensation, n (%) | 1 (3) | 6 (8) | 0·67 | |
| Response to UDCA, n (%) | 12 (48) | 39 (60) | 0·35 | |
| PML (17%) | Mayo risk score, median (IQR) | 4·0 (3·7–4·5) | 4·1 (3·6–4·6) | 0·61 |
| AMA-positive, n (%) | 18 (95) | 85 (94) | 1 | |
| Associated autoimmune conditions, n (%) | 2 (11) | 19 (21) | 0·36 | |
| Hepatic decompensation, n (%) | 1 (5) | 6 (7) | 1 | |
| Response to UDCA, n (%) | 8 (57) | 43 (57) | 1 | |
| GRASP-1 (17%) | Mayo risk score, median (IQR) | 4·0 (3·7–4·8) | 4·1 (3·6–4·6) | 0·85 |
| AMA-positive, n (%) | 17 (94) | 86 (95) | 1 | |
| Associated autoimmune conditions, n (%) | 4 (22) | 17 (19) | 0·75 | |
| Hepatic decompensation, n (%) | 2 (11) | 5 (5) | 0·33 | |
| Response to UDCA, n (%) | 10 (67) | 41 (55) | 0·57 | |
| GW1 (12%) | Mayo risk score, median (IQR) | 4·1 (3·7–4·4) | 4·0 (3·6–4·6) | 0·99 |
| AMA-positive, n (%) | 12 (92) | 91 (95) | 0·54 | |
| Associated autoimmune conditions, n (%) | 1 (8) | 20 (21) | 0·46 | |
| Hepatic decompensation, n (%) | 0 (0) | 7 (7) | 0·6 | |
| Response to UDCA, n (%) | 8 (67) | 43 (55) | 0·54 | |
| CENP-B (11%) | Mayo risk score, median (IQR) | 3·7 (3·3–4·6) | 4·1 (3·7–4·6) | 0·33 |
| AMA-positive, n (%) | 9 (82) | 94 (96) | 0·11 | |
| Associated autoimmune conditions, n (%) | 5 (45) | 16 (16) | 0·04 | |
| Hepatic decompensation, n (%) | 1 (9) | 6 (6) | 0·54 | |
| Response to UDCA, n (%) | 5 (50) | 46 (58) | 0·74 | |
| VCP (11%) | Mayo risk score, median (IQR) | 3·7 (3·0–4·3) | 4·1 (3·7–4·6) | 0·13 |
| AMA-positive, n (%) | 11 (92) | 92 (95) | 0·51 | |
| Associated autoimmune conditions, n (%) | 3 (25) | 18 (19) | 0·7 | |
| Hepatic decompensation, n (%) | 2 (17) | 5 (5) | 0·17 | |
| Response to UDCA, n (%) | 8 (67) | 43 (55) | 0·54 |
AMA, anti-mitochondrial antibodies by IIF; 3E-BPO, branched-chain 2-oxo-acid dehydrogenase complex and 2-oxo glutarate dehydrogenase complex; CENP, centromere protein; GRASP-1, glutamate receptor interacting protein (GRIP)-associated protein-1; PML, promyelocyte leukaemia antigen; UDCA, ursodeoxycholic acid; VCP, valosin-containing protein; IQR, interquartile range.